The role and mechanisms of zinc oxide nanoparticles in the improvement of the radiosensitivity of lung cancer cells in clinically relevant megavoltage radiation energies in-vitro

Document Type : Research Paper


1 Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Radiotherapy Oncology, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran,

3 Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

4 Department of Biosciences and Biotechnology, Malek-Ashtar University of Technology, Tehran, Iran

5 Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

6 Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran


Objective(s): Semiconductor zinc oxide nanoparticles (ZnO NPs) have unique properties, such as inherent selectivity and photosensitization effects under ultraviolet (UV) radiation. ZnO NPs serve as promising anticancer agents. However, UV radiation limits their penetration into the body. In most clinical settings, it is essential to use high-energy photons in the treatment of deep-seated tumors. The present study aimed to evaluate the radiosensitization effects of ZnO NPs on human lung cancer cells under megavoltage (MV) X-ray irradiation.
Materials and Methods: ZnO NPs with the mean diameter of seven nanometers were synthesized and characterized. The cytotoxicity and cellular uptake of ZnO NPs were evaluated in SKLC-6 lung cancer and MRC-5 normal lung cells using the 3-(4,5-dimethylthiazol-yl)-5(3-carboxymethoxyphenyl)-2H-tetrazolium (MTT) and inductively coupled plasma-mass spectrometry assays, respectively. In addition, the radiosensitization effects of ZnO NPs were investigated under MV irradiation using a clonogenic survival assay. Apoptosis induction and DNA damage were also evaluated using flow cytometry and cytokinesis-block micronucleus assay, respectively.
Results: ZnO NPs were taken up and reduced the viability of the cancer cells at a higher rate compared to the normal cells. Moreover, ZnO NPs significantly enhanced the radiosensitivity of the cancer cells with the sensitizer enhancement ratios of 1.23 and 1.31 at the concentrations of 10 and 20 μg/ml, respectively. However, they had no significant effect on the radiosensitivity of the normal cells. Apoptosis induction and DNA damage also improved at a higher rate in the cancer cells compared to the normal cells with the combination of ZnO NPs with MV radiation.
Conclusion: According to the results, ZnO NPs had the potential to be a selective radiosensitizer for lung cancer radiotherapy under MV X-ray irradiation. Some of the cytotoxic and genotoxic mechanisms in radiosensitization by ZnO NPs were elevated apoptosis induction and DNA damage levels.


1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018; 68(6): 394-424.
2.Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Jr., Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017; 389(10066): 299-311.
3.Chargari C, Riet F, Mazevet M, Morel E, Lepechoux C, Deutsch E. Complications of thoracic radiotherapy. Presse Med. 2013; 42(9 Pt 2): 342-351.
4.Salama JK, Vokes EE. New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer. J Clin Oncol. 2013; 31(8): 1029-1038.
5.Wang H, Mu X, He H, Zhang XD. Cancer Radiosensitizers. Trends Pharmacol Sci. 2018; 39(1): 24-48.
6.Liu Y, Zhang P, Li F, Jin X, Li J, Chen W, Li Q. Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells. Theranostics. 2018; 8(7): 1824-1849.
7.Klein S, Sommer A, Distel LV, Neuhuber W, Kryschi C. Superparamagnetic iron oxide nanoparticles as radiosensitizer via enhanced reactive oxygen species formation. Biochem Biophys Res Commun. 2012;425(2):393-397.
8.Morita K, Miyazaki S, Numako C, Ikeno S, Sasaki R, Nishimura Y, Ogino C, Kondo A. Characterization of titanium dioxide nanoparticles modified with polyacrylic acid and H2O2 for use as a novel radiosensitizer. Free Radic Res. 2016; 50(12):1319-1328.
9.Juzenas P, Chen W, Sun YP, Coelho MA, Generalov R, Generalova N, Christensen IL. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev. 2008; 60(15):1600-1614.
10.Generalov R, Kuan WB, Chen W, Kristensen S, Juzenas P. Radiosensitizing effect of zinc oxide and silica nanocomposites on cancer cells. Colloid surface B. 2015;129: 79-86.
11.Zhang H, Patel N, Xiong J, Ding S. Targeting and noninvasive treatment of hepatocellular carcinoma in situ by ZnO nanorod-mediated concurrent chemoradiotherapy. RSC Adv. 2015; 5(104): 85720-85729.
12.Jiang J, Pi J, Cai J. The Advancing of Zinc Oxide Nanoparticles for Biomedical Applications. Bioinorg Chem Appl. 2018; 2018: 18.
13.Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc Oxide Nanoparticles for Selective Destruction of Tumor Cells and Potential for Drug Delivery Applications. Expert Opin Drug Deliv. 2010; 7(9): 1063-1077.
14.Ma H, Wallis LK, Diamond S, Li S, Canas-Carrell J, Parra A. Impact of solar UV radiation on toxicity of ZnO nanoparticles through photocatalytic reactive oxygen species (ROS) generation and photo-induced dissolution. Environ Pollut. 2014; 193: 165-172.
15.Lestari U, Mufti N, Lutfiyah DA, Fitriyah U, Annisa Y. UV Irradiation Enhanced In-Vitro Cytotoxic Effects of ZnO Nanoparticle on Human Breast Cancer. J Phys Conf Ser. 2018; 1093(1): 012046.
16.Ghaemi B, Mashinchian O, Mousavi T, Karimi R, Kharrazi S, Amani A. Harnessing the Cancer Radiation Therapy by Lanthanide-Doped Zinc Oxide Based Theranostic Nanoparticles. ACS Appl Mater Interfaces. 2016; 8(5): 3123-3134.
17.Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and Radiation Therapy: Current Advances and Future Directions. Int J Med Sci. 2012; 9(3): 193-199.
18.AGENCY IAE. Absorbed Dose Determination in External Beam Radiotherapy. Vienna: IAEA; 2000.
19.Subiel A, Ashmore R, Schettino G. Standards and Methodologies for Characterizing Radiobiological Impact of High-Z Nanoparticles. Theranostics. 2016; 6(10): 1651-1671.
20.Jain S, Coulter JA, Hounsell AR, Butterworth KT, McMahon SJ, Hyland WB, Muir MF, Dickson GR, Prise KM, Currell FJ, O’Sullivan JM, Hirst DG. Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies. Int J Radiat Oncol Biol Phys. 2011; 79(2): 531-539.
21.Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc. 2007; 2(5): 1084-1104.
22.Talam S, Karumuri SR, Gunnam N. Synthesis, Characterization, and Spectroscopic Properties of ZnO Nanoparticles. ISRN. 2012; 2012: 6.
23.Brun E, Sicard-Roselli C. Actual questions raised by nanoparticle radiosensitization. Radiat. Phys Chem. 2016; 128: 134-142.
24.Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol. 2016; 11(1): 115.
25.Kolodziejczak-Radzimska A, Jesionowski T. Zinc Oxide-From Synthesis to Application: A Review Materials. 2014; 7(4): 2833-2881.
26.Meißner T, Kathrin O, Potthoff A. Implications of the stability behavior of zinc oxide nanoparticles for toxicological studies. Int Nano Lett. 2014: 4: 116.
27.Akhtar MJ, Ahamed M, Kumar S, Majeed Khan MA, Ahmad J, Alrokayan SA. Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species. Int J Nanomedicine. 2012; 7: 845-857.
28.Bihari P, Vippola M, Schultes S, Praetner M, Khandoga AG, Reichel CA, Coester C, Tuomi T, Rehberg M, Krombach F. Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol. 2008; 5: 14.
29.Moore TL, Rodriguez-Lorenzo L, Hirsch V, Balog S, Urban D, Jud C, Rothen-Rutishauser B, Lattuada M, Petri-Fink A. Nanoparticle colloidal stability in cell culture media and impact on cellular interactions. Chem Soc Rev. 2015; 44(17): 6287-6305.
30.Ancona A, Dumontel B, Garino N, Demarco B, Chatzitheodoridou D, Fazzini W, Engelke H. Lipid-Coated Zinc Oxide Nanoparticles as Innovative ROS-Generators for Photodynamic Therapy in Cancer Cells. Nanomaterials. 2018; 8(3): 143.
31.Cho WS, Duffin R, Thielbeer F, Bradley M, Megson IL, Macnee W, Poland CA, Tran CL, Donaldson K. Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. Toxicol Sci. 2012; 126(2): 469-477.
32.Bisht G, Rayamajhi S. ZnO Nanoparticles: A Promising Anticancer Agent. Nanobiomedicine (Rij). 2016; 3: 9.
33.Pati R, Das I, Mehta RK, Sahu R, Sonawane A. Zinc-Oxide Nanoparticles Exhibit Genotoxic, Clastogenic, Cytotoxic and Actin Depolymerization Effects by Inducing Oxidative Stress Responses in Macrophages and Adult Mice. T Toxicol Sci. 2016; 150(2): 454-472.
34.Shen C, James SA, de Jonge MD, Turney TW, Wright PF, Feltis BN. Relating cytotoxicity, zinc ions, and reactive oxygen in ZnO nanoparticle-exposed human immune cells. Toxicol Sci. 2013; 136(1): 120-130.
35.Reddy KM, Feris K, Bell J, Wingett DG, Hanley C, Punnoose A. Selective toxicity of zinc oxide nanoparticles to prokaryotic and eukaryotic systems. Appl Phys Lett. 2007; 90(213902): 2139021-2139023.
36.Hanley C, Layne J, Punnoose A, Reddy KM, Coombs I, Coombs A, Feris K, Wingett D. Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles. Nanotechnology. 2008; 19(29): 295103.
37.Taccola L, Raffa V, Riggio C, Vittorio O, Iorio MC, Vanacore R, Pietrabissa A, Cuschieri A. Zinc oxide nanoparticles as selective killers of proliferating cells. Int J Nanomedicine. 2011; 6: 1129-1140.
38.Sasidharan A, Chandran P, Menon D, Raman S, Nair S, Koyakutty M. Rapid dissolution of ZnO nanocrystals in acidic cancer microenvironment leading to preferential apoptosis. Nanoscale. 2011; 3(9): 3657.
39.Akhtar MJ, Alhadlaq HA, Kumar S, Alrokayan SA, Ahamed M. Selective cancer-killing ability of metal-based nanoparticles: implications for cancer therapy. Arch Toxicol. 2015; 89(11): 1895-1907.
40.Maggiorella L, Barouch G, Devaux C, Pottier A, Deutsch E, Bourhis J, Borghi E, Levy L. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 2012; 8(9): 1167-1181.
41.Youkhana EQ, Feltis B, Blencowe A, Geso M. Titanium Dioxide Nanoparticles as Radiosensitisers: An In vitro and Phantom-Based Study. Int J Med Sci. 2017; 14(6): 602-614.
42.Khoshgard K, Hashemi B, Arbabi A, Rasaee MJ, Soleimani M. Radiosensitization effect of folate-conjugated gold nanoparticles on HeLa cancer cells under orthovoltage superficial radiotherapy techniques. Phys Med Biol. 2014; 59(9): 2249-2263.
43.Geng F, Song K, Xing JZ, Yuan C, Yan S, Yang Q, Chen J, Kong B. Thio-glucose bound gold nanoparticles enhance radio-cytotoxic targeting of ovarian cancer. Nanotechnology. 2011; 22(28): 285101.
44.McMahon SJ, Hyland WB, Muir MF, Coulter A, Jain S, Butterworth KT, Schettino G, Dickson GR, Hounsell AR, O’Sullivan JM. Nanodosimetric effects of gold nanoparticles in megavoltage radiation therapy. Radiother Oncol. 2011; 100(3): 412-416.
45.Kleinauskas A, Rocha S, Sahu S, Sun YP, Juzenas P. Carbon-core silver-shell nanodots as sensitizers for phototherapy and radiotherapy. Nanotechnology. 2013; 24(32): 325103.
46.Detappe A, Kunjachan S, Rottmann J, Robar J, Tsiamas P, Korideck H, Tillement O, Berbeco R. AGuIX nanoparticles as a promising platform for image-guided radiation therapy. Cancer Nanotechnol. 2015; 6(1): 4.
47.McMahon SJ, Hyland WB, Muir MF, Coulter JA, Jain S, Butterworth KT, Schettino G, Dickson GR, Hounsell AR, O’Sullivan JM, Prise KM, Hirst DG, Currell FJ. Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci Rep. 2011; 1:18.
48.Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ, Knox SJ. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 1998; 58(9): 1779-1784.
49.Saptarshi SR, Duschl A, Lopata AL. Biological reactivity of zinc oxide nanoparticles with mammalian test systems: an overview. Nanomedicine (Lond). 2015; 10(13): 2075-2092.
50.Vandebriel RJ, De Jong WH. A review of mammalian toxicity of ZnO nanoparticles. Nanotechnol Sci Appl. 2012; 5: 61-71.
51.Scherzad A, Meyer T, Kleinsasser N, Hackenberg S. Molecular Mechanisms of Zinc Oxide Nanoparticle-Induced Genotoxicity Short Running Title: Genotoxicity of ZnO NPs. Materials. 2017; 10(12).
52.Movahedi MM, Mehdizadeh A, Koosha F, Eslahi N, Mahabadi VP, Ghaznavi H, Shakeri-Zadeh A. Investigating the photo-thermo-radiosensitization effects of folate-conjugated gold nanorods on KB nasopharyngeal carcinoma cells. Photodiagnosis Photodyn Ther. 2018; 24: 324-331.
53.Hosseini V, Mirrahimi M, Shakeri-Zadeh A, Koosha F, Ghalandari B, Maleki S, Komeili A, Kamrava SK. Multimodal cancer cell therapy using Au@Fe2O3 core-shell nanoparticles in combination with photo-thermo-radiotherapy. Photodiagnosis Photodyn Ther. 2018; 24: 129-135.
54.Khoei S, Mahdavi SR, Fakhimikabir H, Shakeri-Zadeh A, Hashemian A. The role of iron oxide nanoparticles in the radiosensitization of human prostate carcinoma cell line DU145 at megavoltage radiation energies. Int J Radiat Biol.2014; 90(5): 351-356.